-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p
BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention
Watch BeyondSpring's latest callBeyondspring (NASDAQ:BYSI) Q4 2021 Earnings Call · Replay · Apr 14, 2022Read the transcript of Beyondspring (NASDAQ:BYSI) Q4 2021 Earnings CallStory so far
Earlier from BeyondSpring
- BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update
- BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification
- BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients
- BeyondSpring Files 2019 Annual Report on Form 20-F
- BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia
Later from BeyondSpring
- BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
- BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors
- BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020
- BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
- BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
Follow BeyondSpring into a list and get an email when it puts out news.
Follow BeyondSpring